Answers are grounded in this paper and cite their sources.
Demonstrates a validated HPTLC method for simultaneous dissolution testing of telmisartan and hydrochlorothiazide tablets, indicating improved in vitro release in formulated preparations.
A simple, selective, precise and HPTLC method for simultaneous determination of telmisartan and hydrochlorothiazide in the bulk drugs and in their fixed dose combination tablets (FDC) was developed and validated. The method was further applied in the dissolution study of formulated and marketed tablets containing these two drugs. The method employed HPTLC aluminium plates precoated with silica gel 60 F254 as the stationary phase. The solvent system consisted of toluene-ethyl acetate-methanol-glacial acetic acid, 6: 3: 1: 0.5 (v/v). The detection was performed at 272 nm. The RF values were 0.70 ± 2 for telmisartan and 0.44 ± 2 for hydrochlorothiazide. The linear relationships were obtained between peak area and amount of drugs in the range of 1–1000 ng spot−1 with correlation coefficient of 0.9992 for telmisartan and 0.9994 for hydrochlorothiazide. The method was validated for precision, robustness and recovery. The limits of detection and quantification were 15.54 and 48.44 ng spot−1 for telmisartan and 10.22 and 35.68 ng spot−1 for hydrochlorothiazide, respectively. Invitro drug release from prepared tablets showed better drug release when compared with marketed tablets.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: